Subscribe to our newsletter

 

OFDT's latest enables our English-speaking partners to be updated electronically on our latest publications and ongoing projects throughout the year.


To subscribe to OFDT's latest, please use the online form: http://ofdt.systalium.eu/register/

To unsubscribe, please use the appropriate link at the end of a previous newsletter.


Previous OFDT's latest  are available here:

- OFDT's latest n° 8 - 27 June 2017: http://ofdt.systalium.eu/lettre/?lettre=69&contact=3486
- OFDT's latest n° 7 - 10 January 2017: http://ofdt.systalium.eu/lettre/?lettre=62&contact=3486
- OFDT's latest n° 6 - 27 June 2016: http://ofdt.systalium.eu/lettre/?lettre=57&contact=3486
- OFDT's latest n° 5 - 18 April 2016: http://ofdt.systalium.eu/lettre/?lettre=52&contact=3486
- OFDT's latest n° 4 - 23 November 2015: http://ofdt.systalium.eu/lettre/?lettre=44&contact=3486
- OFDT's latest n° 3 - 26 June 2015: http://ofdt.systalium.eu/lettre/?lettre=28&contact=1222
- OFDT's latest n° 2 - 19 November 2014: http://ofdt.systalium.eu/lettre/?lettre=16&contact=1222
- OFDT's latest n° 1 - 26 June 2014: http://ofdt.systalium.eu/lettre/?lettre=16&contact=1222

Drugs in Europe


2017 EMCDDA European Drug Report

What do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions are explored in the 2017 EMCDDA European Drug Report.

Country drug reports

Developed by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.

The European Union and the drug phenomenon

The European Union & the drug phenomenon : Frequently asked questions , joint publication between the EMCDDA and the European Commission, october 2010, 12 p.